Trial Profile
A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 28 Oct 2021 Primary endpoints have been amended.
- 13 Aug 2020 Status changed from active, no longer recruiting to completed.
- 03 Aug 2020 Status changed from recruiting to active, no longer recruiting.